Better Health for All

Dyadic International's core business, centered on its C1 platform, is dedicated to developing proteins for human and animal health, including vaccines and therapeutics.

The company is developing low-cost monoclonal antibodies for malaria and RSV, MERS, H5 Avian Flu, and Mpox vaccines, as well as recombinant proteins like human serum albumin and lactoferrin for various medical applications. These efforts are aimed at improving global health outcomes, particularly by reducing production costs of biologic vaccines and drugs. The company has received a $3 million grant from the Gates Foundation and is eligible for up to $2.4 million from a $4.5 million CEPI grant, specifically targeting affordable treatments for underserved populations in low- and middle-income countries. Research and development expenses were $2.044 million in 2024, representing 58.5% of the $3.495 million total revenue for that year. The company is actively involved in developing vaccines for diseases like Avian Influenza, Mpox, and COVID-19, and is collaborating on affordable rabies prophylactics and vaccines. The company also offers a VaxTech Fridays seminar series.

Honest & Fair Business

Dyadic International, Inc. has a formal Whistleblower Policy, updated March 4, 2022, which explicitly prohibits retaliation against whistleblowers.

It provides specific reporting mechanisms, including direct contact information for the Chief Financial Officer and the Chairman of the Audit Committee, and requires employees to acknowledge they have read and understand the policy. However, there is no evidence of independent investigation processes, training frequency, or program effectiveness. The company also has an Anti-Corruption Policy that explicitly prohibits bribery and kickbacks and addresses anti-bribery laws, including those related to gifts, entertainment, and dealings with government agencies, with specific guidance on international compliance. However, the articles do not provide information on the frequency or effectiveness metrics of its training programs.

Kind to Animals

Dyadic International is actively developing and commercializing animal-free proteins and enzymes, including recombinant serum albumin, dairy enzymes, and whey proteins, as alternatives to traditional animal-derived sources.

The company's C1 fungus technology is presented as an alternative to mammalian cell-based antigen production for vaccines. Dyadic has partnered with Proliant Health and Biologicals, Fermbox Bio, BRIG BIO, and TurtleTree Scientific to develop and commercialize animal-free alternative proteins and growth factors for cruelty-free dairy and meat. Dyadic's CEO advocates for policymakers to invest in pandemic preparedness for human and animal health, and the company's AVATAR project is co-funded by the European Union. However, preclinical studies on a C1-produced monoclonal antibody involved non-human primates and hamsters, and a non-human primate challenge study was completed for a COVID-19 monoclonal antibody, indicating that animal testing is still conducted for some products. The company's R&D expenses decreased to approximately $3.3 million in 2023 from $4.5 million in 2022, with no specific percentage allocated to animal-free technologies.

No War, No Weapons

Dyadic International, Inc.'s core business is biotechnology, with reported revenue from licensing, R&D, and grants for health-related product development, indicating no revenue from arms or defense contracts.

The company's R&D focuses on civilian applications like human serum albumin, enzymes, and vaccine candidates, with no evidence of dual-use technologies. Dyadic has a comprehensive export control and sanctions compliance policy, effective March 1, 2024, which mandates screening all counterparties against the Consolidated Screening List (CSL), OFAC, and EAR restricted parties before any transaction, with biannual re-screening for high-risk parties. The policy explicitly lists sanctioned countries and addresses SDN rules, with periodic testing, audits, and annual employee certifications. The policy also states that all exports require verified end-user certificates, even for civilian goods. There is no evidence regarding peacebuilding investment, conflict divestment, board oversight of defense, lobbying, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, surveillance transparency, war risk audits, annual conflict partner reviews, defense divestment, or conflict minerals.

Planet-Friendly Business

The company has reported zero environmental compliance violations.

While the company's technology aims to reduce the environmental footprint of traditional animal-based protein production and supports sustainable food production, there is no specific quantitative data available for other environmental performance indicators such as greenhouse gas emissions, renewable energy use, water consumption, waste diversion, or climate targets.

Safe & Smart Tech

Dyadic International, Inc. demonstrates good data minimization practices, taking reasonable steps to limit the volume of personal data processed to what is necessary and retaining it only for the minimum period required, which includes the duration of the relationship and applicable legal limitation periods.

The company also shows good regulatory compliance, with its privacy notice last updated in November 2025, including disclosures for U.S. State Privacy Laws (TDPSA and NEDPA), and stating it does not sell or share personal information for cross-context behavioral advertising. For user data control, individuals have rights to access, correct, and request deletion of their personal data, and to object to processing and withdraw consent, which aligns with industry-standard practices. The company processes username, password, and security login details, indicating industry-standard authentication security.

Zero Waste & Sustainable Products

Dyadic's high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products, supporting industrial sustainability goals such as waste valorization and resource-efficient processes.

The company offers microbial enzymes that support carbon reduction and waste valorization in industrial workflows. Dyadic's production systems are GRAS-designated and animal-free, utilizing cost-efficient, animal-free media, and the platform has a low carbon footprint. No specific hazardous waste violations or fines were mentioned in the provided articles.